Advances in Targeting BCR-ABL

Aleksandra Tuzikiewicz, Wiktoria Wawrzyniak, Andrzej Kutner, Teresa Żołek

Abstract readReview

In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aleksandra TuzikiewiczDepartment of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland.

Wiktoria WawrzyniakDepartment of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland.

Andrzej KutnerDepartment of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland.ORCID 0000-0002-9518-4142

Teresa ŻołekDepartment of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland.ORCID 0000-0002-6781-0329

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to imatinib remains a therapeutic challenge, largely driven by point mutations within the kinase domain of the

Indexed as

Antineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylateMutationProtein Kinase InhibitorsDrug Resistance, NeoplasmHumansTyrosine Kinase InhibitorsAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsTyrosine Kinase InhibitorsBCR-ABL tyrosine kinasechronic myeloid leukemiacomputational modelinginhibitorsligand-protein interactionsmedicinal chemistryT315I mutationtargeted therapy

Identifiers

PMID41599389

DOI10.3390/molecules31020341

PMCPMC12843680

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.